BCL2 and prostate cancer: This is supported by the observation in prostate cancer models that loss of BCL2, such as in the BCL2 null cell line (DU145), corresponds with resistance to paclitaxel, while a BCL2 expressing cell line (PC3) is sensitive to paclitaxel [39].